Exosomes Market Size & Forecast 2035
Global Exosomes Market reached US$ 1.74 billion in 2025 and is expected to reach US$ 7.41 billion by 2035, growing at a CAGR of 15.6% during the forecast period 2026-2035. Exosomes, small vesicles 30 to 200 nm, are secreted from cells to mediate signaling in the tumor necrosis factor (TNF)-induced mesenchymal stem cells (TME). Oncogenic EGFR can be shed from cells and interact with other TME cells. Exosomes from gastric cancer cells can regulate the liver microenvironment and promote liver metastasis. EGFR-containing exosomes can be captured by endothelial cells, eliciting EGFR-dependent responses and VEGF secretion. Exosomes from EGFR-mutated NSCLC can promote CD8+ T cell apoptosis, potentially affecting immunotherapy efficacy.
Key Takeaways
- Strong Double-Digit Growth: The global exosomes market is projected to expand from US$1.74 billion in 2025 to US$7.41 billion by 2035, reflecting sustained demand driven by precision medicine and advanced diagnostics.
- Cancer Diagnostics Remain the Core Growth Engine: Rising global cancer incidence is accelerating the adoption of exosome-based liquid biopsy technologies for early diagnosis, treatment monitoring, and biomarker discovery.
- Kits & Reagents Lead Commercial Adoption: Accounting for 47.3% of market revenue, kits and reagents remain the largest segment due to their critical role in standardized exosome isolation, detection, and research workflows.
- Technology Standardization is the Key Market Bottleneck: Challenges related to exosome isolation, purity, scalability, and lack of standardized protocols continue to limit broader clinical and commercial adoption.
- North America Maintains Market Leadership: Supported by strong research funding, advanced healthcare infrastructure, and robust intellectual property activity, North America is expected to hold 38.4% of the global market.
- Clinical Translation is Driving Competitive Advantage: Companies are increasingly investing in exosome-based therapeutics, diagnostics, and CDMO capabilities, signaling a shift from research-focused applications toward commercial-scale manufacturing.
- Asia-Pacific Represents the Highest Long-Term Growth Opportunity: Expanding biotechnology investments, increasing oncology research, and improving healthcare infrastructure position Asia-Pacific as the fastest-growing regional market through 2035.
Exosomes Market Scope
| Metrics | Details |
| CAGR | 15.6% |
| Market Size Available for Years | 2023-2035 |
| Estimation Forecast Period | 2026-2035 |
| Revenue Units | Value (US$ Bn) |
| Segments Covered | Product Type, Application, End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia-Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
Market Dynamics: Drivers & Restraints
Rise in the prevalence of cancers
The increasing prevalence of cancer has led to a growing demand for innovative therapies. Exosome-based technologies, such as liquid biopsy, are being used to analyze biomarkers in bodily fluids like blood, urine, or saliva. Exosomes, as stable carriers of molecular information, are ideal candidates for liquid biopsy approaches. Researchers are exploring the use of exosomal biomarkers for disease progression, treatment response, and detecting minimal residual disease.
For instance, according to the National Center for Health Statistics, In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases; otherwise, however, incidence trends were more favorable in men compared to women.
Technical complexity of exosome isolation and technological limitations
Exosomes, characterized by their size, composition, and cargo, present a technical challenge in isolating them with high purity and specificity. The absence of standardized methods can lead to variability in experimental outcomes and hinder comparability between studies. The isolation process is technically demanding due to the presence of other extracellular vesicles and contaminants. Obtaining pure and high-yield exosome isolation requires sophisticated techniques, which can affect the quality and consistency of the obtained samples.
Exosomes Market Segmentation
The global exosomes market is segmented based on product type, application, end-user, and region.
The kits and reagents from the product type segment accounted for approximately 47.3% of the exosomes market share
The kits and reagents from the product type segment accounted for approximately 47.3%. Kits and reagents are essential tools in exosome research and clinical applications. They facilitate the isolation, detection, and analysis of exosomes from biological samples like blood, urine, and cell culture media. These tools ensure high yield and purity while preserving biological integrity. Kits simplify the isolating process, making it accessible to those with limited technical expertise. Reagents, like antibodies and dyes, label and detect exosomal surface markers, enabling the characterization of exosome cargo. This is crucial for diagnostics, particularly in identifying biomarkers for diseases like cancer, neurodegenerative disorders, and cardiovascular conditions.
For instance, in July 2023, Shimadzu Corporation developed Exorapid-qIC, an immunochromatography kit for extracellular vesicles (CD9) launched by Dai Nippon Toryo Co., Ltd., it is the world's first kit targeting exosomes. The kit includes gold nanoplate-labeled antibodies, immunochromatography test paper, and rinse solution. Shimadzu is responsible for detecting EV types and optimizing the detection system.
Geographical Analysis
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to the rising government funding for the detection of new biomarkers and the increasing incidence of chronic conditions, such as cardiovascular diseases and cancer. In addition, growing research & development activities for the development of novel drugs, diagnostic methods, and treatment options are anticipated to drive the segment growth.
For instance, in July 2024, Aruna Bio, a leader in neural exosome-based therapeutics for neurodegenerative conditions, received a US Patent No. 11,993,787 for its lead program, AB126, an exosome derived from neural stem cells. The patent, which extends protection covering the composition of matter for AB126 and products for gene therapy using AB16, is expected to be granted by 2038.
Market Segmentation
By Product Type
- Kits and Reagents
- Instruments
- Others
By Application
- Cancer Applications
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Other
- Non-Cancer Applications
By End User
- Diagnostics
- Hospitals & Clinical Testing Laboratories
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
The major global players in the market include STARTEK Health, Diagenode Inc., Fujifilm Holdings Corporation, Hitachi Chemical Diagnostics Inc., Lonza, MBL International, Miltenyi Biotec, Novus Biologicals, Qiagen, Thermo Fisher Scientific Inc. among others.
Thermo Fisher Scientific
Thermo Fisher Scientific is one of the world's largest suppliers of life science research tools and offers one of the broadest portfolios for exosome research. Through its Thermo Scientific and Invitrogen brands, the company provides reagents, antibodies, magnetic beads, RNA isolation kits, flow cytometry reagents, qPCR solutions, and analytical instruments used throughout exosome isolation, characterization, purification, and downstream molecular analysis. The company's life sciences portfolio supports both academic research and biopharmaceutical development, making it a key supplier for exosome-based diagnostics and therapeutic research.
Exosome Product Portfolio
- Exosome isolation reagents
- Total exosome RNA & protein isolation kits
- Magnetic bead-based purification solutions
- Exosome antibodies and biomarkers (CD9, CD63, CD81)
- Flow cytometry and imaging solutions
- qPCR and NGS sample preparation solutions
Strategic Position
Thermo Fisher's competitive advantage lies in offering an end-to-end workflow—from sample preparation to molecular characterization—supported by a global commercial network and strong biopharma customer base. The company continues to invest in life sciences technologies that support extracellular vesicle and exosome research.
QIAGEN
QIAGEN is a global leader in sample preparation and molecular diagnostics. Its exosome portfolio focuses primarily on nucleic acid extraction and biomarker discovery. The company provides specialized kits for purification of exosomal RNA and microRNA from plasma, serum, urine, and cell culture media, supporting liquid biopsy research and precision oncology applications. Exosome workflows are integrated with QIAGEN's PCR, digital PCR, and next-generation sequencing platforms, enabling comprehensive biomarker analysis.
Exosome Product Portfolio
- exoRNeasy kits for extracellular vesicle RNA isolation
- miRNA extraction technologies
- Liquid biopsy sample preparation
- Digital PCR workflows
- NGS library preparation solutions
- Bioinformatics software for biomarker analysis
Strategic Position
According to its annual reports, QIAGEN continues prioritizing investments in molecular diagnostics, digital PCR, and sample technologies, positioning exosome-based liquid biopsy research as a complementary growth area within its precision medicine strategy. Its strong expertise in RNA extraction provides a competitive advantage in exosome biomarker discovery.
Miltenyi Biotec
Miltenyi Biotec is a leading developer of cell separation and extracellular vesicle technologies. The company offers dedicated products for exosome isolation, purification, characterization, and analysis. Its proprietary magnetic bead technologies enable high-purity exosome enrichment from biological fluids and cell culture media. Miltenyi's solutions are widely adopted in regenerative medicine, immunology, oncology, and cell and gene therapy research.
Exosome Product Portfolio
- Exosome isolation kits
- Exosome purification columns
- CD9, CD63, and CD81 antibody panels
- Magnetic bead-based extracellular vesicle enrichment
- Flow cytometry solutions
- Automated sample preparation systems
Strategic Position
Miltenyi Biotec differentiates itself through its expertise in magnetic cell separation and automation technologies. Its integrated extracellular vesicle workflow supports translational research and clinical applications, making it a preferred technology partner for academic institutions, biotechnology companies, and pharmaceutical developers working on exosome therapeutics and diagnostics.
Why These Three Companies Lead the Exosomes Market
| Company | Primary Strength in Exosomes | Competitive Advantage |
| Thermo Fisher Scientific | Complete research workflow | Broadest portfolio of reagents, instruments, and analytical solutions |
| QIAGEN | Exosomal RNA & liquid biopsy | Industry-leading nucleic acid extraction and molecular diagnostics |
| Miltenyi Biotec | Isolation & characterization | Advanced magnetic bead technology and extracellular vesicle expertise |
Key Developments
- May 2026 – NurExone Receives South Korean Patent Grant for ExoPTEN - NurExone received a Notice of Patent Grant in South Korea for its lead exosome-based therapy ExoPTEN, strengthening its global intellectual property portfolio for nerve regeneration therapies.
- April 2026 – NurExone Secures Australian Patent for Exosome Manufacturing Technology - NurExone expanded its IP portfolio with an Australian patent covering stem cell-derived exosome production technology, reinforcing long-term commercialization and manufacturing capabilities.
- April 2026 – Exo-Top and BioXtek Sign Strategic Manufacturing Agreement - Exo-Top, NurExone's U.S. subsidiary, signed a strategic agreement with BioXtek to establish GMP manufacturing and commercialization of mesenchymal stem cell-derived exosome therapeutics, supporting clinical-scale production.
- February 2026 – Evox Therapeutics Expands Exosome Gene-Editing Collaboration - Evox Therapeutics partnered with the Rett Syndrome Research Trust to advance its ExoEdit exosome platform for targeted gene-editing therapies in neurological disorders, broadening the therapeutic potential of engineered exosomes.
- January 2026 – Pandorum Technologies Partners with Nucelion Therapeutics. Pandorum Technologies entered a strategic collaboration with Nucelion Therapeutics (Bharat Biotech Group) to scale GMP manufacturing of exosome-based regenerative therapies for the Asia-Pacific market, accelerating commercial production capabilities.
- In January 2024, EXO Biologics SA, a Belgian biotech company committed to developing biopharmaceuticals using exosomes to treat rare diseases with high unmet medical needs, launched ExoXpert, a contract development and manufacturing organization (CDMO) specializing in exosomes. ExoXpert offers an MSC-based exosome manufacturing platform used in European clinical trials and is a wholly-owned subsidiary of EXO Biologics.
Why Purchase the Report?
- To visualize the global exosomes market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of the exosomes market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global exosomes market report would provide approximately 64 tables, 61 figures, and 286 pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
